- Conditions
- Acute Graft-versus-host Disease
- Interventions
- Efmarodocokin Alfa
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Duarte, California • Los Angeles, California • Miami, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 31,368
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Erectile Dysfunction, Sexual Dysfunction, Physiological
- Interventions
- Levitra (Vardenafil, BAY38-9456), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 11
- States / cities
- Laguna Hills, California • Jeffersonville, Indiana • Des Moines, Iowa + 8 more
- Conditions
- Infections
- Interventions
- Ceftaroline fosamil, Ceftriaxone plus vancomycin
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more
- Conditions
- Multiple Sclerosis
- Interventions
- Placebo, 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Imprime PGG, MK-3475
- Drug
- Lead sponsor
- Lawrence Feldman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
- Conditions
- T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
- Interventions
- Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2040
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- NSCLC, Ovarian Cancer, Melanoma, Other Solid Tumors
- Interventions
- LXH254, PDR001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- Coagulation Delay
- Interventions
- phytonadione
- Dietary Supplement
- Lead sponsor
- James A. Haley Veterans Administration Hospital
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- COVID-19
- Interventions
- Hydroxychloroquine, Azithromycin
- Drug
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 1,550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Murray, Utah • Salt Lake City, Utah
- Conditions
- Blepharoptosis
- Interventions
- Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine, Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine
- Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Healthy
- Interventions
- Seltorexant High Dose, Seltorexant Low Dose
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Cilengitide, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Hereditary Angioedema Types I and II
- Interventions
- Ecallantide subcutaneous dosing
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 2 Years to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Mineola, New York
- Conditions
- Cocaine Dependency
- Interventions
- CPP-115, Placebo
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cognitive Deficits in Schizophrenia
- Interventions
- ABT-126, Placebo
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 20 Years to 55 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 23
- States / cities
- Cerritos, California • Costa Mesa, California • Escondido, California + 19 more
- Conditions
- Major Depressive Disorder
- Interventions
- Levomilnacipran ER, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 23
- States / cities
- Dothan, Alabama • Highlands Ranch, Colorado • Boca Raton, Florida + 18 more
- Conditions
- Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
- Interventions
- Semaglutide Pill, Fresh organic vegetables
- Drug · Dietary Supplement
- Lead sponsor
- Sansum Diabetes Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
- Interventions
- PHIN-214 Subcutaneous injection
- Drug
- Lead sponsor
- PharmaIN
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Chandler, Arizona • Coronado, California • Marrero, Louisiana + 5 more
- Conditions
- SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
- Interventions
- JAG201
- Genetic
- Lead sponsor
- Jaguar Gene Therapy, LLC
- Industry
- Eligibility
- 2 Years to 9 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Osanetant
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
- Interventions
- REM-422
- Drug
- Lead sponsor
- Remix Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- San Francisco, California • Tampa, Florida • Boston, Massachusetts + 4 more
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Timolol Gel, Placebo Gel
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Metastatic Urothelial Carcinoma, Bladder Cancer
- Interventions
- Pembrolizumab, Cryoablation, Avelumab
- Drug · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Deep Venous Thrombosis, Pulmonary Embolism
- Interventions
- Low dose nadroparin, Intermediate dose nadroparin, Low dose enoxaparin, Intermediate dose enoxaparin, Low dose dalteparin, Intermediate dose dalteparin, Fixed low dose tinzaparin, Intermediate dose tinzaparin
- Drug
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1,110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York